help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pinna, G.
Right arrow Articles by Baumgartner, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pinna, G.
Right arrow Articles by Baumgartner, A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Brain Cancer
The Journal of Clinical Endocrinology & Metabolism Vol. 83, No. 9 3071-3077
Copyright © 1998 by The Endocrine Society


Original Studies

3,3'-Diiodothyronine Concentrations in the Sera of Patients with Nonthyroidal Illnesses and Brain Tumors and of Healthy Subjects during Acute Stress1

Graziano Pinna, Luis Hiedra, Harald Meinhold, Murat Eravci, Hans Prengel, Oliver Brödel, Klaus-Jürgen Gräf, Gisela Stoltenburg-Didinger, Michael Bauer and Andreas Baumgartner

Departments of Radiology and Nuclear Medicine, Neuropathology (G.S.-D.) and Psychiatry (M.B.), Universitätsklinikum Benjamin Franklin, Free University of Berlin, and the Department of Medicine (K.-J.G.), Universitätsklinikum Rudolf Virchow, Humboldt University, 12200 Berlin, Germany

Address all correspondence and requests for reprints to: Dr. Andreas Baumgartner, Department of Radiological Diagnostics and Nuclear Medicine, Hindenburgdamm 30, 12200 Berlin, Germany.


    Abstract
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
In this article we describe the development of a highly sensitive, accurate, and reproducible RIA for the measurement of 3,3'-diiodothyronine (3,3'-T2) in human serum and brain tissue. The detection limits were 1.8 fmol/g and 1.5 pmol/L in human brain tissue and serum, respectively.

Serum concentrations of 3,3'-T2 were measured in 4 groups of patients with nonthyroidal illnesses (NTI), i.e. brain injuries (n = 15), sepsis (n = 24), liver disease (n = 22), and brain tumors (n = 23). The mean serum concentration of 3,3'-T2 in 62 healthy controls was 46.6 ± 20.0 pmol/L. 3,3'-T2 levels declined significantly with increasing age. They were significantly lower in patients with brain injury (34.2 ± 19.4 pmol/L; P = 0.006), were at the upper limit of normal in patients with sepsis (57.0 ± 36.9 pmol/L; P = 0.06), and were elevated in patients with liver disease (72.6 ± 56.7 pmol/L; P = 0.04) and brain tumors (89.0 ± 40.9 pmol/L; P = 0.01). The serum levels of T3 were significantly lower than those in controls in all 4 patient groups. Serum concentrations of 3,3'-T2 were significantly enhanced in 9 patients with hyperthyroidism (85.4 ± 43.0 pmol/L; P = 0.01) and were reduced in 12 patients with hypothyroidism (14.9 ± 9.2 pmol/L; P = 0.001). In both normal brain tissue, obtained either intraoperatively or excised postmortem, and brain tumors, the concentrations of 3,3'-T2 ranged between 50–300 fmol/g. In healthy controls, 2 different forms of acute stress (sleep deprivation and delivering a lecture) significantly increased serum levels of T4 and T3, but did not affect those of 3,3'-T2 or 3,5-T2.

In conclusion, our results show that, contrary to expectation, a low T3 syndrome in NTI is not always associated with low serum concentrations of 3,3'-T2. The production of 3,3'-T2 in NTI seems to be regulated in a disease-specific manner, resulting in unchanged, reduced, or elevated hormone concentrations.


    Introduction
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
MANY SYSTEMIC nonthyroidal illnesses (NTI) are associated with specific changes in serum concentrations of thyroid hormones, namely decreases in T3 (low T3 state) and T4 (low T3 and T4 state) and increases in rT3 levels (1, 2, 3). Neither the mechanisms responsible for low T3 states nor their metabolic impact are as yet fully understood (2, 3). Patients with various somatic disorders frequently have subnormal serum concentrations of thyroid hormones over prolonged periods, but fail to exhibit clinical features of hypothyroidism. Recent findings have shown that the low T3 state is probably not due to an inhibition of outer ring deiodinase activity alone, but that several different pathways of thyroid hormone metabolism may also be affected. Two study groups have found elevated serum concentrations of T3 sulfate in patients with NTI (4, 5). Our own group recently reported elevated serum levels of 3,5-diiodothyronine (3,5-T2) in patients with four different NTIs (6). Enhanced production of T3 sulfate and 3,5-T2 may be a mechanism that is responsible for lowering T3 concentrations in certain tissues. It is therefore interesting to establish whether another major pathway of T3 degradation (inner ring deiodination to 3,3'-T2) may also be altered in NTI. Several studies have measured serum levels of 3,3'-T2 in patients with NTI. Gavin et al. (7) reported normal serum levels of 3,3'-T2 in 10 patients with NTI, whereas Faber et al. (8) found normal concentrations of 3,3'-T2 in patients with liver cirrhosis, but low levels in patients with uremia, malignancies, and myocardial infarction. The latter group, however, also reported reduced 3,3'-T2 concentrations in patients with liver cirrhosis (9), whereas Wu et al. found reduced 3,3'-T2 levels in this disease (10). Two groups reported elevated serum concentrations of 3,3'-T2 in hyperthyroidism and reduced levels in hypothyroidism (10, 11). Low serum levels of 3,3'-T2 have also been measured in patients with anorexia nervosa (12), and elevated hormone concentrations have been found in umbilical cord sera of newborns (10, 11, 12, 13). In light of these contradictory findings, we considered it justifiable to reinvestigate the serum levels of 3,3'-T2 in patients with NTI. For this purpose, we developed a new 3,3'-T2 RIA with improved sensitivity in the lower range. Using this RIA, the serum concentrations of 3,3'-T2 were measured in four groups of patients with NTI whose serum concentrations of 3,5-T2, T3, T4, free T4, and TSH have been reported previously (6). We also measured levels of 3,3'-T2 in healthy brain tissue and brain tumors to investigate whether changes in serum levels of 3,3'-T2 are accompanied by corresponding changes in the affected tissues.

Patients with NTI may suffer from different forms of relatively severe stress, e.g. fear, fever, sleep disturbances, etc. We therefore investigated the effects of two acute stressors, i.e. sleep deprivation and delivering a lecture, on the serum concentrations of 3,3'-T2 and 3,5-T2 in healthy volunteers to study the reactivity of these hormones in response to external stimuli.


    Subjects and Methods
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Patients and controls

The patients and healthy controls were the same as those whose serum levels of 3,5-T2 had been previously reported (6).

The serum concentrations of 3,3'-T2 were measured in the following patients and control samples.

Patients with sepsis. Twenty-four patients admitted to the intensive care unit, either postoperatively or after trauma, and whose clinical course was complicated by sepsis were studied. Ten of these patients had peritonitis, and 14 had pneumonia. Ten were women, and 14 were men; their mean age was 56.2 ± 19.0 yr (range, 16–89 yr). The diagnosis of sepsis was established according to criteria previously published (14).

Patients with liver disease. The serum levels of the two iodothyronines were measured in 22 patients with severe liver disease before liver transplantation. Nine were women, and 13 men; their mean age was 50.4 ± 30.2 yr (range, 23–82 yr). The patients were suffering from various underlying liver diseases, such as chronic hepatitis, Morbus Wilson, hemochromatosis, and alcoholic cirrhosis.

Patients with head and/or brain injury. Fifteen patients admitted to an intensive care unit with a diagnosis of closed head injury were also studied. Six of these patients were women, and 9 were men; their mean age was 36.2 ± 33.8 yr (range, 28–44 yr). Blood samples were drawn from all patients during the first 2 days after the injury, when the subjects were still in an unconscious state. The critically ill patients admitted to the intensive care unit were treated with appropriate antibiotics and various drugs given to stabilize vital functions. When necessary, in patients with sepsis and head injuries hemodynamic stabilization was achieved by controlled volume load, dobutamine, and, where required, norepinephrine. Four patients with sepsis were also given dopamine. None of these patients was receiving glucocorticoids. Patients with known thyroid disorders or thyroid hormone supplementation were not included in the study. All patients received 30–35 cal/kg BW daily either enterally or parenterally (70% in carbohydrate form and 30% in lipid form). Amino acids (1.5 g/kg BW) were also given.

Patients with brain tumors. Twenty-three patients hospitalized for brain surgery in the Department of Neurosurgery were also investigated. Twelve were women, and 11 were men; their mean age was 50.1 ± 12.5 yr (range, 22–70 yr). Six of these patients had a glioblastoma, 5 had meningioma, 4 had astrocytoma, and 5 were scheduled for removal of brain metastases, their primary tumors being at a different site. The general condition of all of these patients was relatively good. None of them was suffering from a severe concomitant disease. Blood samples were drawn immediately before the operation, i.e. during full anesthesia. The anesthetics propofol and fentanyl and a muscle relaxant were employed.

Patients with thyroid disorders. Nine patients with hyperthyroidism (6 women and 3 men; mean age of 36.3 ± 4.5 yr; range, 28–44 yr) and 12 patients with hypothyroidism (8 women and 4 men; mean age of 46.7 ± 5.6 yr; range, 37–59 yr) were also studied before treatment for the underlying thyroid disorder was instituted.

Healthy controls. Sixty-two healthy subjects were studied for comparison. Thirty-two of them were women, and 30 were men; their mean age was 47.3 ± 18 yr (range, 22–89 yr). As an age dependence of 3,3'-T2 levels has been reported in previous studies (8, 15), we took care to include large enough percentages of all relevant age groups in the control group. Ten subjects were between 20–30 yr of age, 10 were between 30–40 yr, 9 were between 40–50 yr, 11 were between 50–60 yr, 9 were between 60–70 yr, 9 were between 70–80 yr, and 4 were over 80 yr. The subjects below 60 yr of age were employees of various departments of the Klinikum Benjamin Franklin who were personally known to the authors. Controls older than 60 yr were healthy retired volunteers who occasionally work for a drug research institute and whose good and stable state of health had been documented in the records of this institute for a period of several years. None of the controls had any apparent clinical illness at the time of the investigation or any history or current signs of thyroid disorder, or was currently taking thyroid hormones or any other medication known to affect serum concentrations of thyroid hormones, such as oral contraceptives or ß-adrenergic blockers (16, 17).

All blood samples from the patients and healthy controls were always drawn in the morning between 0700–1000 h. As blood samples were drawn from all patients routinely for diagnostic purposes, this opportunity was used to obtain 5 mL additional blood to determine thyroid hormone levels for research purposes.

Samples of normal human tissue were collected by the Department of Neurosurgery and Neuropathology of the Klinikum Benjamin Franklin, respectively. They had been excised during neurosurgical operations (n = 5) for therapeutic purposes or at autopsy (n = 5) for histopathological investigation. Samples from various regions of the brain (cortex, hippocampus, pons, and cerebellum) were obtained from donors at autopsy, which was performed between 24–96 h after death. Between death and autopsy, the bodies were stored at 4–6 C. Four of the donors were male, and one was female; their mean age was 58.4 ± 12.5 yr (range, 36–70 yr). They had died of different disorders not primarily affecting the brain, such as lymphoma, myocardial infarction, diabetes mellitus, primary pulmonary hypertension, and dilated cardiomyopathy. The effects of storage temperature and the time interval between death and autopsy on thyroid hormone concentrations were investigated in the striata of male Sprague-Dawley rats (n = 12). After decapitation, the brain regions of the controls (n = 4) were immediately frozen on dry ice and stored at -70 C until assay. The tissue from the two additional groups (each n = 4) was kept at room temperature for 4 h. Thereafter, it was stored at 4 C for 24 and 96 h, respectively, before freezing. This design was chosen to simulate postmortem events in humans.

Five samples of healthy tempo-cortical lobe tissue were obtained during temporal lobe resection in patients with temporal lobe epilepsy. Pieces of tumor tissue were obtained during surgery from the patients from whom serum samples had been collected (see above). Tissues obtained at operation were immediately frozen in liquid nitrogen and stored at -70 C until assay.

An night of sleep deprivation was performed in six healthy male subjects, all of whom were physicians working at the Klinikum Benjamin Franklin. Their mean age was 32 ± 3 yr (range, 27–37 yr). An indwelling catheter was inserted in the cubital vein in all subjects at 2000 h. Blood was drawn at 20-min intervals between 2200–0600 h. During this period the subjects were not permitted to sleep. They spent the night together watching television, reading, or playing games. All of them also spent 3 control nights of sleep in a sleep laboratory. The first 2 nights served for adaptation, and on the third night an iv catheter attached to a tube passed through a hole in the wall into the next room was placed in the forearm. Each volunteer retired to bed at 2100 h, and the lights were switched off at 2200 h. Blood samples were drawn every 20 min between 2200–0600 h. Electroencephalogram recordings were performed during the same period.

In the second stress experiment, blood samples were drawn from 10 physicians before and after delivering a lecture at a clinical conference. This type of stress has previously been shown to induce pronounced increases in serum cortisol (18). The conference took place between 1500–1700 h. Thus, four blood samples were collected: one at 1500 h and one at 1700 h on the day of the conference and two additional samples at 1500 and 1700 h, respectively, on a control day not less than 1 week later.

Hormone determinations

Reagents. Tetraiodothyroacetic acid (Tetrac), triiodothyroacetic acid (Triac), diiodothyroacetic acid (Diac), T4, T3, rT3, 3,5-diiodo-L-thyronine (3,5-T2), 3,3'-diiodo-L-thyronine (3,3'-T2), 3',5'-diiodo-L-thyronine (3',5'-T2), and thyronine of highest available purity as well as 3,3'-T2 conjugate to BSA for antibody production were purchased from Henning Berlin (Berlin, Germany). Mercury-[(O-carboxyphenyl)thio]ethyl sodium salt (merthiolate), L-cysteine, and BSA were purchased from Sigma Chemical Co. (St. Louis, MO). The tracer 3-bromo-[5-125I]thyronine (3-Br-[5-125I]T1) was provided by R. Thoma, Formula GmbH (Berlin, Germany). Phosphate buffer (0.04 mol/L; pH 8.0) containing 243 mg/L merthiolate and 2 g/L BSA served as the experimental buffer. The iodoamino acids were dissolved in 0.1 mol/L sodium hydroxide and diluted to final assay concentrations using this buffer. Either the 3-Br-[5-125I]T1 tracer or the 3,3'-T2 tracer was dissolved in experimental buffer containing 100 mg/L L-cysteine. The stop solution formed by the experimental buffer, 30% (wt/vol) polyethylene glycol and 1.3 mg/mL bovine {gamma}-globulin was pipetted (1 mL/tube) to precipitate the antibody-bound radioactivity in either the 3,3'-T2 or the 3,5-T2 RIA.

Synthesis of 3,3'-T2 tracer. Labeled 3,3'-T2 of maximum specific radioactivity was obtained by radioiodination of 3-iodo-L-thyronine with chloramine-T (19). 3-Iodo-L-thyronine was dissolved in 0.01 mol/L sodium hydroxide, chloramine-T (Merck, Darmstadt, Germany), and sodium disulfite in 0.1 mol/L phosphate buffer, pH 7.0. For labeling, 10-µL volumes of the following reagents were pipetted into a Microflex vial (Radiochemical Center, Amersham, Aylesbury, UK) containing 40 µL 0.5 mol/L phosphate buffer (pH 7.5), 37 megabecquerels (1 mCi) 125I (~0.5 nmol iodine; Radiochemical Center, Amersham), 2 nmol 3-iodo-L-thyronine, and 0.2 µmol chloramine-T. After an incubation period of 30 s, 1.5 µmol sodium disulfite were added. The reaction mixture was injected onto the high performance liquid chromatography (HPLC) column. HPLC separation of 3,3'-T2 was carried out using a 5-µm Eurospher 100-C18, 4 x 250-mm column (Knauer, Berlin, Germany). The column was equilibrated with a gradient of 100% methanol and 0.02 mol/L ammonium acetate buffer, pH 4.0 (volumes, 55 and 45 mL), at a flow rate of 1 mL/min. After running the gradient, the column was washed with 100% methanol at a flow rate of 1 mL/min for 30 min to remove contaminants that elute from the column. 3'-T1 and 3,3'-T2 eluted from the column after 9 and 22 min, respectively. The fraction eluting from the HPLC column corresponding to the 3,3'-[125I]T2 peak was collected and eluted with 100% methanol containing 0.25% concentrated ammonia. This solution was stored at -20 C. The radiochemical purity was tested by thin layer chromatography (silica gel 60 F254 plates, Merck) in ethyl acetate-methanol-3 mol/L ammonia (volumes, 50, 20, and 10 mL). The Rf values were 0.15 and 0.30 for 3,3'-T2 and 3'-T1, respectively.

Preparation of 3,3'-T2-binding antiserum. Antiserum to 3,3'-T2 was produced in three rabbits immunized by serial injections of a conjugate of 3,3'-T2 to BSA in complete Freund’s adjuvant as described previously (20). All immunized rabbits produced antisera satisfactory for RIA of 3,3'-T2. The antiserum selected for experiments was obtained after three injections of the immunogen, 8 weeks after starting immunization. It was used in a final dilution of 1:150,000, which bound about 40% of tracer in an incubation volume of 250 µL.

Preparation of test samples. For the serum 3,3'-T2 or 3,5-T2 measurements, serum was extracted with 2 vol dehydrated alcohol, evaporated to dryness, and taken up in the experimental buffer. The tissue concentrations of 3,3'-T2 were determined after extraction of the tissue samples, as previously described (21) with some modifications. In brief, tissue samples were homogenized using a solution containing methanol (100%) and 1 mmol/L 6-n-propyl-2-thiouracil (PTU), extracted twice in the homogenization solution, and purified through Bio-Rad AG 1 x 2 resin columns (Bio-Rad Laboratories, Richmond, CA). The iodothyronines were eluted with 70% acetic acid, evaporated to dryness for approximately 2 h at room temperature by using a speed vacuum pump (Virtis Co., New York, NY) incorporating a refrigerating system (-20 C), and taken up into the experimental buffer. Both 3,3'-T2 and 3,5-T2 appeared to be relatively stable during evaporation of the serum/tissue extracts (the recoveries of known concentrations of 3,3'-T2 and 3,5-T2 were 96 ± 5.6% and 93 ± 4.7%, respectively). Extracts from either 200 µL original serum or approximately 100 mg tissue were processed individually and assayed together within the same run. Each sample was determined in triplicate. The results were corrected on the basis of individual recovery data obtained after the addition of tracer (~1000 cpm/tube) during the initial extraction process. This amount of tracer did not affect the RIA measurements. The extraction procedure yielded mean recoveries of 82.1 ± 3.4% (range, 73.6–88.1%) and 85.3 ± 3.8% (range, 77.2–94.1%) for 3,5-T2 and 3,3'-T2, respectively.

RIA procedure for 3,3'-T2. The RIA of 3,3'-T2 in serum and extracted tissue was carried out in 10 x 55-mm plastic tubes, adding various reagents as follows: 1) experimental buffer to give a final volume of 250 µL/tube, 2) 50 µL 3,3'-T2 standard at concentrations ranging from 0.49–60 fmol/tube (for the serum measurements, standards were diluted in experimental buffer containing the same volume of ethanol-extracted hormone-free serum as the unknown samples), and 3) 100 µL tracer solution containing around 6000 cpm 3,3'-T2. After 24-h incubation at room temperature, the antibody-bound iodothyronine portion was precipitated by adding 1 mL polyethylene glycol stop solution, prepared by adding to the experimental buffer 30% (wt/vol) polyethylene glycol and 2.3 mg/L bovine {gamma}-globulin, and centrifuged. The supernatant was discarded, and precipitated bound radioactivity was counted. The RIA procedure for 3,5-T2 was performed as previously described (6). To ensure that thawing the serum samples twice had no effect on the serum concentrations of 3,3'-T2, three different samples of serum from healthy controls were thawed and refrozen five times. The concentrations of 3,3'-T2 were measured each time after thawing. The results showed that repeated thawing had no effect on the serum hormone concentrations.

In all patients the serum concentrations of T4, free T4, T3, rT3, and TSH were measured as previously described (6, 22, 23). For each assay, hormone determinations were performed on the serum samples drawn from the patient groups together with those from some of the healthy controls.

Data analysis. The data are presented as the mean ± SD, and P < 0.05 was considered significant. The mean ± 2 SD were regarded as within the normal range. Linear regression analysis was conducted to evaluate the effects of age and sex on 3,3'-T2 concentrations in the healthy subjects. Comparison of hormone concentrations of the patients and controls was performed using the Mann-Whitney U test. For comparison of hormone concentrations in the two stress experiments, we applied the Wilcoxon rank test.


    Results
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
Assay validation

Figure 1Go represents the standard curve showing the displacement of the 3,3'-T2 tracer from the specific antibody to 3,3'-T2 effected by increasing concentrations of nonradioactive 3,3'-T2. The statistics reveal significant inhibition of 3,3'-[125I]-T2 binding after the addition of 3,3'-T2 concentrations as low as 0.3 fmol/tube. This sensitivity threshold allowed detection of 1.8 fmol/g and 1.5 pmol/L 3,3'-T2 in the tissue and serum, respectively.



View larger version (12K):
[in this window]
[in a new window]
 
Figure 1. Standard curve for 3,3'-T2. Increasing concentrations of nonradioactive 3,3'-T2 were added to displace the binding of the 3,3'-[125I]T2 tracer and its specific antibody.

 
Dilutions of serum extracts from 3,3'-T2-enriched sera and two serum samples from hyperthyroid patients and from two tissue extracts yielded curves that were essentially parallel to the standard curve (data not shown).

The inter- and intraassay coefficients of variation (CVs) for tissue samples were determined in more than five tests. The intraassay CVs ranged between 6.8–7.2, and the interassay CVs ranged between 7.4–8.6. The measurements were performed using two different samples, both of which caused 50% inhibition of 3,3'-T2 antibody binding.

Table 1Go shows the proportions of various iodothyronines and iodotyrosines, tested in four or five different concentrations, that bound to the specific antibody to 3,3'-T2. Cross-reaction of the antibody to 3,3'-T2 with the majority of the compounds tested was minimal. In particular, only 0.04% of the Triac reacted with the 3,3'-T2 antibody.


View this table:
[in this window]
[in a new window]
 
Table 1. Relative cross-reactivities of several iodothyronines with 3,3'-T2 antibody

 
Table 2Go shows the effects of several drugs used for the treatment of intensive care patients on the binding of 3,3'-[125I]T2 to its specific antibody. Two of the 12 drugs tested showed no detectable effects. The highest cross-reactivity was measured for fentanyl (2 x 10-5). The cross-reactivities of all other drugs were between 1–5 orders of magnitude lower.


View this table:
[in this window]
[in a new window]
 
Table 2. Cross-reactivities of various drugs with antiserum to 3,3'-T2

 
The mean (±SD) recoveries from 4.7, 20, and 78 pmol/L nonlabeled 3,3'-T2 added to pooled serum obtained from euthyroid patients were 97.9 ± 6.6%, 95 ± 8.2%, and 98.7 ± 7.3%, respectively.

Serum concentrations of 3,3'-T2 in patients and controls

The mean serum concentration of 3,3'-T2 for the group of healthy controls (n = 62) was 46.6 ± 20.0 pmol/L. Linear regression analysis conducted to investigate the effects of age and gender on the variable "hormone" revealed a significant age effect (t = -3.661; P = 0.006). Thus, the 3,3'-T2 concentrations declined significantly with increasing age. No effect of sex was noted (t = 0.715; P = 0.48). The four groups of patients with NTI differed considerably with respect to age (see Materials and Methods). We, therefore, established a specific age- and sex-matched control group for each patient group.

Figure 2Go shows the full results for the serum concentrations of 3,3'-T2 in the controls and different patient groups. The serum levels of 3,3'-T2 were significantly enhanced in patients with hyperthyroidism (P = 0.01) and were subnormal in those with hypothyroidism (P = 0.001). In the group of patients with NTI, serum levels of 3,3'-T2 were lower than those in the controls in patients with brain injury (P = 0.006), were normal in patients with sepsis (P = 0.06), and were elevated in patients with liver disease (P = 0.04) and brain tumors (P = 0.01). The normal range of 3,3'-T2 was defined as the mean ± 2 SD. Although the serum levels of 3,3'-T2 in the patients with brain injury were significantly reduced, the values of all but 2 patients were still within the normal range. In contrast, 9 of the 24 patients with sepsis had 3,3'-T2 concentrations above the normal range, although their mean levels of 3,3'-T2 did not differ significantly from those measured in the corresponding control group. Six of the 22 patients with liver disease and 12 of the 23 patients with brain tumors had elevated serum levels of 3,3'-T2.



View larger version (26K):
[in this window]
[in a new window]
 
Figure 2. Serum concentrations of 3,3'-T2 in healthy subjects and patients with thyroidal and nonthyroidal illnesses. Values are given as the mean ± SD. The hatched areas indicate the normal range. The hormone measurements in the samples of each patient group were performed together with those in the samples of the respective age- and sex-matched control subjects.

 
The concentrations of T4, free T4, T3, rT3, and TSH in the six patient groups and the healthy controls have been published previously (6). In brief, all four patient groups had significantly lower serum levels of T3 and significantly enhanced levels of rT3. The patients with liver disease and those with brain tumors also had significantly reduced serum concentrations of T4.

The results of the stress experiments are presented in Tables 3Go and 4Go. For the sleep deprivation experiment we calculated the mean values for each hormone measured in all blood samples between midnight and 0600 h and compared these values with those obtained during the night of sleep, using the Wilcoxon rank test. From Table 3Go it can be seen that sleep deprivation induced a highly significant increase in the serum concentrations of T4, T3, and TSH, but remained without effect on those of 3,5-T2 and 3,3'-T2.


View this table:
[in this window]
[in a new window]
 
Table 3. Mean thyroid hormone concentrations of six healthy volunteers measured at 20-min intervals between 0000–0600 h during nights of sleep and sleep deprivation, respectively (see Materials and Methods)

 

View this table:
[in this window]
[in a new window]
 
Table 4. Thyroid hormone and cortisol serum concentrations in 10 physicians before (1500 h) and after (1700 h) delivering a lecture and on a control day

 
Table 4Go shows that delivering a lecture induced significant increases in the serum levels of T4 (at 1500 h) and T3 (at both 1500 and 1700 h). However, no significant effects were observed on 3,5-T2 or 3,3'-T2. The increases in TSH concentrations at 1500 h on the day of the lecture failed to reach statistical significance (P = 0.1; Table 4Go). However, TSH levels were significantly higher at 1500 h, before the lecture, than after it, at 1700 h (P = 0.01). No such difference occurred on the control day. The concentrations of cortisol were also measured to better evaluate the severity of the stress effects. They were significantly elevated at both measuring times (Table 4Go).

Tissue concentrations of 3,3'-T2 in patients and controls

Concentrations of 3,3'-T2 in tissue from different parts of the brain obtained from five donors at autopsy and in samples obtained from the temporal and occipital cortex during neurosurgery are shown in Fig. 3AGo. 3,3'-T2 was detectable in all tissue samples; the concentrations ranged between 50–300 fmol/g. The concentrations of 3,3'-T2 in different brain tumors are shown in Fig. 3BGo. They ranged between 15–350 fmol/g. The highest concentrations were found in glioblastomas (281 ± 61 fmol/g), and the lowest in astrocytomas (20 ± 6 fmol/g). The tissue levels of T4, T3 and 3,5-T2 in these samples have been reported previously (6). The results of the experiments conducted to evaluate the effects of postmortem delay on iodothyronine concentrations are presented in Fig. 4Go. This figure shows that storing the brain samples at 4 C for 24 h led to a fall in tissue concentrations of hormones of between 11–27% (T4, -11%; T3, -16%; 3,3'-T2, -27%; 3,5-T2, -15%). The respective decreases after a storage period of 96 h at 4 C before freezing induced a 43% reduction in T4 levels, a 28% fall in T3 concentrations, a 50% fall in 3,3'-T2, and a 29% fall in 3,5-T2. These data imply that the 3,3'-T2 levels measured in the different regions of the adult human brain at autopsy and presented in Fig. 3Go are probably 30–50% too low. This is consistent with the fact that the concentrations of 3,3'-T2 measured in the tissue samples obtained intraoperatively (Cx in Fig. 3aGo) were indeed approximately 30% higher than those determined in tissue obtained postmortem.



View larger version (19K):
[in this window]
[in a new window]
 
Figure 3. 3,3'-T2 concentrations in samples from different regions of the adult human brain and pituitary, obtained either at autopsy or intraoperatively (A). 3,3'-T2 concentrations in tissue samples in different forms of human brain tumors and metastases are shown (B). Crb, Cerebellum; Cf, frontal cortex; Str, striatum; Pit, pituitary; Cx, occipito-temporal cortex; Met, metastasis; Ast, astrocytomas; Glb, glioblastomas; Men, meningiomas.

 


View larger version (23K):
[in this window]
[in a new window]
 
Figure 4. Tissue concentrations of T4 (A), T3 (B), 3,5-T2 (C), and 3,3'-T2 (D) obtained from the striata of rats (n = 4) at different intervals postmortem (see Materials and Methods).

 

    Discussion
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 
The main finding of the present study is the complexity of the changes in the serum levels of 3,3'-T2 in the four patient groups with different NTIs. 3,3'-T2 measurements were obtained using a RIA with improved sensitivity in the lower range [at least 2-fold more sensitive than those reported to date (7, 8, 10, 15)]. It allowed the clear detection of 3,3'-T2 in various human brain areas, in different kinds of brain tumors, and in almost all hypothyroid serum samples. In two of the four patient groups with NTIs, the concentrations of 3,3'-T2 were significantly enhanced, and another group showed increases that failed to reach statistical significance. In the fourth group, the levels were significantly reduced. The only reports on this issue in the literature showed either normal (7, 8) or reduced (8) serum concentrations of 3,3'-T2 in different NTIs. Whereas the levels of T3 are subnormal in NTIs, and those of rT3 are higher than normal, the changes in the concentrations of 3,3'-T2 would seem to be disease specific, and both elevated and reduced concentrations may be found depending on the illness concerned. Why the levels of 3,3'-T2 should change in different directions in different diseases is not immediately evident. The changes in the levels of 3,3'-T2 could depend on the severity of the NTI. In two of our patient populations (those with brain tumors and liver diseases), we measured lower than normal serum concentrations of T4. This may indicate that these patients had a rather severe form of NTI. However, in the two other diagnostic groups (sepsis and head injury), the serum levels of T4 were normal, indicating that these patients had a milder form of NTI. The patients with brain tumors had by far the lowest serum levels of T4 and T3 (6), but the highest levels of 3,3'-T2. Patients with liver diseases had the second lowest serum levels of T3 and T4 and also the second highest levels of 3,3'-T2. Conversely, the patients with brain injury who had normal serum levels of T4 and only modestly reduced serum concentrations of T3 had low levels of 3,3'-T2. It would therefore seem that the more severely ill patients with NTI are, the lower their concentrations of both T3 and T4 become, and the higher their serum levels of 3,3'-T2 rise. Further studies are needed to confirm this observation.

Whereas reduced serum levels of 3,3'-T2 may simply result from a decrease in the availability of T3, the mechanisms leading to a rise in 3,3'-T2 production are presently unclear. 3,3'-T2 may be produced from T3 by inner ring deiodination or from rT3 by outer ring deiodination. The activity of type I 5'-deiodinase is said to be inhibited in NTI (1, 2, 3), which should result in lower, rather than higher, production of 3,3'-T2 from both rT3 and T3. However, an enhanced availability of rT3 as substrate could nevertheless contribute to an increase in the production of 3,3'-T2. To our knowledge there is as yet no experimental evidence of inhibition of the outer ring type II 5'-deiodinase (2, 3). Furthermore, inner ring deiodination of T3 may be catalyzed by different enzymes, e.g. type I 5'-deiodinase and type III 5-deiodinase, whose characteristics seem to vary from tissue to tissue (24). As far as we are aware, nothing definitive is known about the activities of these enzymes in the tissues of patients with NTI. The possibility that the specific inner ring deiodinase enzyme in diseased tissue is enhanced can therefore not be excluded at this point. Moreover, deiodination of T3 is facilitated by sulfation (25). Serum concentrations of T3 sulfate are indeed enhanced in patients with NTI (4, 5). On the other hand, desulfation may occur in human and rat tissues (26). Hypothetically, the elevated levels of 3,3'-T2 may derive from T3 sulfate via deiodination and desulfation. Finally, the possibility that specific changes in the metabolism or clearance rate of 3,3'-T2 in different NTIs may contribute to the changes in its serum concentrations cannot currently be excluded.

Another question that remains unanswered at present is whether the changes in the concentrations of 3,3'-T2 have some physiological significance. Several researchers have now reported various effects of 3,5-T2 on cellular respiration and other parameters (27, 28, 29, 30, 31, 32, 33), but in most cases rather high doses of hormone were needed to achieve this effect. A few studies have also reported effects of 3,3'-T2 on rat liver cytochrome oxidate activity and respiratory rate (29, 30). However, possible metabolic effects of 3,3'-T2 remain to be confirmed by in vivo experiments, and it is thus not yet possible to draw any conclusions regarding the physiological significance of the altered 3,3'-T2 concentrations in NTI.

NTIs are associated with different forms of stress, such as pain or fear. To evaluate whether stress effects are involved in the changes in diiodothyronines in NTI, we measured 3,5-T2 and 3,3'-T2 after two different forms of acute stress. Both during sleep deprivation and while delivering a lecture, the serum concentrations of T3 and T4 rose, but those of 3,5-T2 and 3,3'-T2 remained unchanged. Rises in the serum levels of T3 and T4 and also of TSH during sleep deprivation have frequently been reported (34, 35). Although TSH concentrations on the stress day were not significantly elevated as compared with those on the control day, the fact that the TSH levels were significantly higher before the lecture than they were afterward militates in favor of an involvement of TSH in the rises in serum concentrations of T4 and T3 during this kind of stress. As these increases in T3 and T4 occur in parallel, they are most likely due to enhanced secretion from the thyroid gland. Our results, therefore, suggest that 3,5-T2 and 3,3'-T2 are not directly secreted by the thyroid after the experience of an acute stressful stimulus and are not sensitive to acute psychological stress of up to 6-h duration.


    Footnotes
 
1 Presented at the 24th Annual Meeting of the European Thyroid Association, Munich, Germany, August 30 to September 3, 1997 (36 ). This work was supported by a grant from the University of Cagliari, Cagliari, Italy (to G.P.). Back

Received September 24, 1997.

Revised February 25, 1998.

Revised May 12, 1998.

Accepted May 20, 1998.


    References
 Top
 Abstract
 Introduction
 Subjects and Methods
 Results
 Discussion
 References
 

  1. Wartofsky L, Burmann KD. 1982 Alterations in thyroid function in patients with systemic illness: the "euthyroid sick syndrome." Endocr Rev. 3:164–217.[Abstract/Free Full Text]
  2. Nicoloff JT, LoPresti JS. 1996 Nonthyroidal illness. In: Bravermann LE, Utiger RD, eds. Werner and Ingbars’s the thyroid: a fundamental and clinical text, 7th ed. Philadelphia: Lippincott; 288–296.
  3. Chopra IJ. 1996 Nonthyroidal illness syndrome or euthyroid sick syndrome? Endocr Pract. 2:45–52.
  4. Chopra IJ, Wu SY, Teco GNC, Santini F. 1992 A radioammunoassay for measurement of 3,5,3'-triiodothyronine sulfate: studies in thyroidal and nonthyroidal diseases, pregnancy, and neonatal life. J Clin Endocrinol Metab. 75:189–194.[Abstract]
  5. Santini F, Chiovato L, Bartalena L, et al. 1996 Study of serum 3,5,3'-triiodothyronine sulfate concentration in patients with systemic nonthyroidal illness. Eur J Endocrinol. 134:45–49.[Abstract/Free Full Text]
  6. Pinna G, Meinhold H, Hiedra L, et al. 1997 Elevated 3,5-diiodothyronine concentrations in the sera of patients with nonthyroidal illnesses and brain tumors. J Clin Endocrinol Metab. 82:1535–1542.[Abstract/Free Full Text]
  7. Gavin LA, Hammond ME, Castle JN, Cavalieri RR. 1978 3,3'-Diiodothyronine production, a major pathway of peripheral iodothyronine metabolism in man. J Clin Invest. 5:1276–1285.
  8. Faber J, Kirkegaard C, Lumholtz IB, Siersbaek-Nielsen K, Friis T. 1979 Measurements of serum 3',5'-diiodothyronine and 3,3'-diiodothyronine concentrations in normal subjects and in patients with thyroid and nonthyroid disease: studies of 3',5'-diiodothyronine metabolism. J Clin Endocrinol Metab. 48:611–617.[Abstract/Free Full Text]
  9. Faber J, Thomsen F, Lumholtz IB, Kirkegaard C, Siersbaek, et al. 1981 Kinetic studies of thyronine, 3,5,3'-triiodothyronine, 3,3',5'-triiodothyronine, 3',5'-diiodothyroniine, 3,3'-diiodothyroniine, and 3'-monoiodothyronine in patients with liver cirrhosis. J Clin Endocrinol Metab. 53:978–984.[Abstract/Free Full Text]
  10. Wu SY, Chopra IJ, Nakamura Y, Solomon DH, Bennett LR. 1976 A radioimmunoassay for measurement of 3,3'-L-diiodothyronine (T2). J Clin Endocrinol Metab. 43:682–685.[Abstract/Free Full Text]
  11. Burman KD, Strum D, Dimond RC, et al. 1977 A radioimmunoassay for 3,3'-L-diiodothyronine (3,3'-T2). J Clin Endocrinol Metab. 45:339–342.[Abstract/Free Full Text]
  12. Burger A, Sakoloff C. 1977 Serum 3,3'-L-diiodothyronine, a direct radioimmunoassay in human serum: method and clinical results. J Clin Endocrinol Metab. 45:384–391.[Abstract/Free Full Text]
  13. Geola I, Chopra IJ, Solomon DH, Maciel RMB. 1979 Metabolic clearance and production rates of 3',5'-diiodothyronine and 3,3'-diiodothyronine in man. J Clin Endocrinol Metab. 48:297–301.[Abstract/Free Full Text]
  14. Meinhold H, Gramm HJ, Meissner W, et al. 1991 Elevated serum diiodotyrosine (DIT) in severe infections and sepsis: DIT, a possible new marker of leukocyte activity. J Clin Endocrinol Metab. 72:945–953.[Abstract/Free Full Text]
  15. Nishikawa M, Inada M, Naito K, et al. 1981 Age-related changes of serum 3,3'-diiodothyronine, 3',5'-diiodothyronine, and 3,5-diiodothyronine concentrations in man. J Clin Endocrinol Metab. 52:517–522.[Abstract/Free Full Text]
  16. Wenzel KW. 1981 Pharmacological interference with in vitro tests of thyroid function. Metabolism. 30:717–732.[CrossRef][Medline]
  17. Davies PH, Franklyn JA. 1991 The effects of drugs on tests of thyroid function. Eur J Clin Pharmacol. 40:439–451.[CrossRef][Medline]
  18. Baumgartner A, Gräf KJ, Kürten I. 1985 The dexamethasone suppression test in depression, in schizophrenia, and during experimental stress. Biol Psychiatry. 20:675.[CrossRef][Medline]
  19. Nakamura Y, Chopra IJ, Solomon DH. 1977 Preparation of high-specific-activity radioactive iodothyronines and their analogues. J Nucl Med. 18:1112–1115.[Abstract/Free Full Text]
  20. Meinhold H. 1986 Radioimmunoassay of iodothyronines. In: Hennemann G, ed. Thyroid hormone metabolism. New York: Marcel Dekker; 133–186.
  21. Morreale de Escobar G, Pastor R, Obregon MJ, Escobar del Rey F. 1985 Effects of maternal hypothyroidism on the weight and thyroid hormone content of rats embrionic tissues, before and after onset of fetal thyroid function. Endocrinology. 117:1890–1900.[Abstract/Free Full Text]
  22. Baumgartner A, Gräf KJ, Kürten I, Meinhold H. 1988 The hypothalamic pituitary thyroid axis in psychiatric patients and healthy subjects. II. Repeated measurements of thyroxine, free thyroxine, triiodothyronine, free triiodothyronine, and reverse triiodothyronine in patients with major depressive disorder and schizophrenia and healthy subjects. Psychiatr Res. 24:283–306.[CrossRef]
  23. Baumgartner A, Riemann D, Berger M. 1990 Neuroendocrinological investigations during sleep deprivation in depression. II. Longitudinal measurement of thyrotropin, TH, cortisol, prolactin, GH, and LH during sleep and sleep deprivation. Biol Psychiatry. 28:569–587.[CrossRef][Medline]
  24. Leonard JL, Köhrle J. 1996 Intracellular pathways of iodothyronine metabolism. In: Braverman LE, Utiger RD, eds. The thyroid, 7th ed. Lippincott: Philadelphia; 125–161.
  25. LoPresti J, Nicoloff JT. 1994 3,5,3'-triiodothyronine (T3) sulfate: a major metabolite in T3 metabolism in man. J Clin Endocrinol Metab. 78:688.[Abstract]
  26. Kung MP, Spaulding SW, Roth JA. 1988 Desulfation of 3,5,3'-triiodothyronine sulfate by microsomes from human and rat tissues. Endocrinology. 122:1195.[Abstract/Free Full Text]
  27. Horst C, Rokos H, Seitz HJ. 1989 Rapid stimulation of hepatic oxygen consumption by 3,5-diiodo-L-thyronine. Biochem J. 261:945–950.[Medline]
  28. Horst C, Harneit A, Seitz HJ, Rokos H. 1995 3,5-Diiodo-L-thyronine suppresses TSH in rats in vivo and in rat pituitary fragments in vitro. J Endocrinol. 145:291–297.[Abstract/Free Full Text]
  29. Lanni A, Moreno M, Cioffi M, Goglia F. 1993 Effect of 3,3'-diiodothyronine and 3,5-diiodothyronine on rat liver mitochondria. J Endocrinol. 136:59–64.[Abstract/Free Full Text]
  30. Lanni A, Moreno M, Lombardi A, Goglia F. 1994 Rapid stimulation in vitro of rat liver cytochrome oxidase activity by 3,5-diiodo-L-thyronine and by 3,3'-diiodo-L-thyronine. Mol Cell Endocrinol. 99:89–94.[CrossRef][Medline]
  31. O’Reilly I, Murphy MP. 1992 Studies on the rapid stimulation of mitochondrial respiration by thyroid hormones. Acta Endocrinol (Copenh). 127:542–546.[Abstract/Free Full Text]
  32. Cimmino M, Mion F, Goglia F, Minaire Y, Géloen. 1996 Demonstration of in vivo metabolic effects of 3,5-di-iodothyronine. J Endocrinol. 149:319–325.[Abstract/Free Full Text]
  33. Baur A, Bauer K, Jarry H, Köhrle J. 1997 3,5-Diiodo-L-thyronine stimulates type I 5'deiodinase activity in rat anterior pituitaries in vivo and in reaggregate cultures and GH3 cells in vitro. Endocrinology. 138:3242–3248.[Abstract/Free Full Text]
  34. Parker DC, Pekary AE, Hershman JM. 1976 Effects of normal and reversed sleep-wake cycles upon nyctohemeral rhythmicity of plasma thyrotropin: evidence suggestive of an inhibitory influence in sleep. J Clin Endocrinol Metab. 43:318–329.[Abstract/Free Full Text]
  35. Baumgartner A, Dietzel M, Saletu B, et al. 1993 Influence of partial sleep deprivation on the secretion of thyrotropin, thyroid hormones, growth hormone, prolactin, luteinizing hormone, follicle stimulation hormone, and estradiol in healthy young women. Psychiat Res. 48:153–178.[CrossRef][Medline]
  36. Pinna G, Hiedra L, Eravci M, Meinhold H, Baumgartner A. 1997 3,5- and 3,3'-diiodothyronine serum and tissue levels in nonthyroidal illness. J Endocrinol Invest. 20:114.



This article has been cited by other articles:


Home page
Integr. Comp. Biol.Home page
T. Flatt, L. L. Moroz, M. Tatar, and A. Heyland
Comparing thyroid and insect hormone signaling
Integr. Comp. Biol., December 1, 2006; 46(6): 777 - 794.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
G. Pinna, O. Brodel, T. Visser, A. Jeitner, H. Grau, M. Eravci, H. Meinhold, and A. Baumgartner
Concentrations of Seven Iodothyronine Metabolites in Brain Regions and the Liver of the Adult Rat
Endocrinology, May 1, 2002; 143(5): 1789 - 1800.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
M. Moreno, A. Lombardi, L. Beneduce, E. Silvestri, G. Pinna, F. Goglia, and A. Lanni
Are the Effects of T3 on Resting Metabolic Rate in Euthyroid Rats Entirely Caused by T3 Itself?
Endocrinology, February 1, 2002; 143(2): 504 - 510.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
M. Eravci, G. Pinna, H. Meinhold, and A. Baumgartner
Effects of Pharmacological and Nonpharmacological Treatments on Thyroid Hormone Metabolism and Concentrations in Rat Brain
Endocrinology, March 1, 2000; 141(3): 1027 - 1040.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pinna, G.
Right arrow Articles by Baumgartner, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pinna, G.
Right arrow Articles by Baumgartner, A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Brain Cancer


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals